Literature DB >> 29364214

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation.

Lisa Kozicky1, Laura M Sly2.   

Abstract

Macrophages are phagocytic innate immune cells, which initiate immune responses to pathogens and contribute to healing and tissue restitution. Macrophages are equally important in turning off inflammatory responses. We have shown that macrophages stimulated with intravenous immunoglobulin (IVIg) can produce high amounts of the anti-inflammatory cytokine, interleukin 10 (IL-10), and low levels of pro-inflammatory cytokines in response to bacterial lipopolysaccharides (LPS). IVIg is a polyvalent antibody, primarily immunoglobulin Gs (IgGs), pooled from the plasma of more than 1,000 blood donors. It is used to supplement antibodies in patients with immune deficiencies or to suppress immune responses in patients with autoimmune or inflammatory conditions. Infliximab, a therapeutic anti-tumor necrosis factor alpha (TNFα) antibody, has also been shown to activate macrophages to produce IL-10 in response to inflammatory stimuli. IVIg and other antibody-based biologics can be tested to determine their effects on macrophage activation. This paper describes methods for derivation, stimulation, and assessment of murine bone marrow macrophages activated by antibodies in vitro and murine peritoneal macrophages activated with antibodies in vivo. Finally, we demonstrate the use of western blotting to determine the contribution of specific cell signaling pathways to anti-inflammatory macrophage activity. These protocols can be used with genetically modified mice, to determine the effect of a specific protein(s) on anti-inflammatory macrophage activation. These techniques can also be used to assess whether specific biologics may act by changing macrophages to an IL-10-producing anti-inflammatory activation state that reduces inflammatory responses in vivo. This can provide information on the role of macrophage activation in the efficacy of biologics during disease models in mice, and provide insight into a potential new mechanism of action in people. Conversely, this may caution against the use of specific antibody-based biologics to treat infectious disease, particularly if macrophages play an important role in host defense against that infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29364214      PMCID: PMC5908398          DOI: 10.3791/56689

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  31 in total

1.  Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors.

Authors:  J S Gerber; D M Mosser
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.

Authors:  Anne Christine W Vos; Manon E Wildenberg; Ingrid Arijs; Marjolijn Duijvestein; Auke P Verhaar; Gert de Hertogh; Séverine Vermeire; Paul Rutgeerts; Gijs R van den Brink; Daniel W Hommes
Journal:  Inflamm Bowel Dis       Date:  2011-09-20       Impact factor: 5.325

3.  Biochemical and functional characterization of three activated macrophage populations.

Authors:  Justin P Edwards; Xia Zhang; Kenneth A Frauwirth; David M Mosser
Journal:  J Leukoc Biol       Date:  2006-08-11       Impact factor: 4.962

Review 4.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

Review 5.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

6.  The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production.

Authors:  Paul Gallo; Ricardo Gonçalves; David M Mosser
Journal:  Immunol Lett       Date:  2010-07-27       Impact factor: 3.685

7.  Intravenous immune globulin in autoimmune and inflammatory diseases.

Authors:  Erwin W Gelfand
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

8.  Western blot: technique, theory and trouble shooting.

Authors:  Zhi-Qiang Liu; Tahrin Mahmood; Ping-Chang Yang
Journal:  N Am J Med Sci       Date:  2014-03

9.  Rituximab and its potential for the treatment of rheumatoid arthritis.

Authors:  Adam Bryant; John Moore
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.